Genetics etiologies and genotype phenotype correlations in a cohort of individuals with central conducting lymphatic anomaly.
Journal
European journal of human genetics : EJHG
ISSN: 1476-5438
Titre abrégé: Eur J Hum Genet
Pays: England
ID NLM: 9302235
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
received:
08
10
2021
accepted:
10
05
2022
revised:
03
05
2022
pubmed:
24
5
2022
medline:
9
9
2022
entrez:
23
5
2022
Statut:
ppublish
Résumé
Central conducting lymphatic anomaly (CCLA) is a heterogenous disorder caused by disruption of central lymphatic flow that may result in dilation or leakage of central lymphatic channels. There is also a paucity of known genetic diagnoses associated with CCLA. We hypothesized that specific genetic syndromes would have distinct lymphatic patterns and this would allow us to more precisely define CCLA. As a first step toward "precision lymphology", we defined the genetic conditions associated with CCLA by performing a retrospective cohort study. Individuals receiving care through the Jill and Mark Fishman Center for Lymphatic Disorders at the Children's Hospital of Philadelphia between 2016 and 2019 were included if they had a lymphangiogram and clinical genetic testing performed and consented to a clinical registry. In our cohort of 115 participants, 26% received a molecular diagnosis from standard genetic evaluation. The most common genetic etiologies were germline and mosaic RASopathies, chromosomal abnormalities including Trisomy 21 and 22q11.2 deletion syndrome, and PIEZO1-related lymphatic dysplasia. Next, we analyzed the dynamic contrast magnetic resonance lymphangiograms and found that individuals with germline and mosaic RASopathies, mosaic KRASopathies, PIEZO1-related lymphatic dysplasia, and Trisomy 21 had distinct central lymphatic flow phenotypes. Our research expands the genetic conditions associated with CCLA and genotype-lymphatic phenotype correlations. Future descriptions of CCLA should include both genotype (if known) and phenotype to provide more information about disease (gene-CCLA). This should be considered for updated classifications of CCLA by the International Society of Vascular Anomalies.
Identifiants
pubmed: 35606495
doi: 10.1038/s41431-022-01123-9
pii: 10.1038/s41431-022-01123-9
pmc: PMC9436962
doi:
Substances chimiques
Ion Channels
0
PIEZO1 protein, human
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1022-1028Subventions
Organisme : NCATS NIH HHS
ID : TL1 TR001880
Pays : United States
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2022. The Author(s), under exclusive licence to European Society of Human Genetics.
Références
Pediatr Radiol. 2019 May;49(5):586-592
pubmed: 30613845
Clin Genet. 2021 May;99(5):742-743
pubmed: 33433009
Eur J Hum Genet. 2016 May;24(5):690-6
pubmed: 26242988
Radiology. 2014 Nov;273(2):410-6
pubmed: 24988434
Eur J Hum Genet. 2021 Jan;29(1):51-60
pubmed: 32788663
Nat Commun. 2015 Sep 03;6:8085
pubmed: 26333996
J Magn Reson Imaging. 2021 Jun;53(6):1766-1790
pubmed: 33625795
Nat Med. 2019 Jul;25(7):1116-1122
pubmed: 31263281
Pediatrics. 2020 Dec;146(6):
pubmed: 33219052
Vasa. 2015 Mar;44(2):92-105
pubmed: 25698387
Hum Mol Genet. 2018 Sep 15;27(18):3233-3245
pubmed: 29905864
Circ Res. 2021 Jun 25;129(1):136-154
pubmed: 34166072
Pediatr Blood Cancer. 2021 Apr 12;:e28985
pubmed: 33844431
Tech Vasc Interv Radiol. 2016 Dec;19(4):255-261
pubmed: 27993320
Clin Dysmorphol. 2021 Apr 1;30(2):89-92
pubmed: 32925199
Pediatrics. 2015 Jul;136(1):e203-14
pubmed: 26055853
Sci Transl Med. 2022 Mar 2;14(634):eabm4869
pubmed: 35235341
Eur Radiol. 2019 Oct;29(10):5190-5196
pubmed: 30887210
Am J Hum Genet. 2021 Jan 7;108(1):8-15
pubmed: 33417889